1374036-52-8

Upstream product

• 1191426-29-5 ((2R,3R)-3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)oxiran-2-yl)methanol 
• 1374036-46-0 (4S)-4-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-2-(4-methoxyphenyl)-1,3-dioxane 
• 1374036-47-1 (S)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-(4-methoxybenzyloxy)butan-1-ol 
• 1374036-48-2 tert-butyl((S)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-(4-methoxybenzyloxy)butoxy)diphenylsilane 
• 1374036-49-3 (2S,4S)-6-[1-(tert-butyl)-1,1-diphenylsilyl]oxy-4-[(4-methoxybenzyl)oxy]hexane-1,2-diol 
• 1374036-51-7 tert.-butyl((S)-3-(4-methoxybenzyloxy)-4-((S)-oxiran-2-yl)butoxy)diphenylsilane 
• 1826-67-1 vinyl magnesium bromide 
• 1374036-50-6 C₃₇H₄₆O₇SSi 
• 1374036-45-9 (S)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)butane-1,3-diol 
• 2186-92-7 p-Anisaldehyde dimethyl acetal 
• 633305-66-5 (R)-tert-butyl-(3-(4-methoxybenzyloxy)hex-5-enyloxy)-diphenylsilane 
• 854749-30-7 (S)-5-((tert-butyldiphenylsilyl)oxy)-3-((4-methoxybenzyl)oxy)pentanal 
• 1730-25-2 allylmagnesium bromide 
• 112897-09-3 (3R)-1-(tert-butyldiphenylsilyloxy)hex-5-en-3-ol 

Downstream Products

• 1374036-54-0 (3S,5R)-3-(4-methoxybenzyloxy)-5-(methoxymethoxy)oct-7-en-1-ol 
• 1374036-44-8 (3R,5R)-3-(4-methoxybenzyloxy)-5-(methoxymethoxy)oct-7-enoic acid 
• 1374036-42-6 (4R,6S,8S)-6-methoxy-8-methyldec-9-en-4-yl (3R,5R)-3-(4-methoxybenzyloxy)-5-(methoxym-ethoxy)oct-7-enoate 
• 1374036-53-9 (5R,7S)-5-allyl-7-(4-methoxybenzyloxy)-12,12-dimethyl-11,11-diphenyl-2,4,10-trioxa-11-silatridecane 
• 1609354-55-3 C₃₂H₄₀O₄Si 

Relevant academic research and scientific papers

Total synthesis of biselyngbyolide A

Biselyngbyolide A is an 18-membered macrolide that exhibits significant biological activities such as growth-inhibitory activity and apoptosis inducing activity against cancer cells. In this study, the first total synthesis of biselyngbyolide A by using a

Synthesis of the macrolactone core of (+)-neopeltolide by transannular cyclization

The synthesis of the macrolactone core of (+)-neopeltolide has been achieved. The key synthetic strategy involves the highly diastereoselective synthesis of the 2,6-cis-disubstituted tetrahydropyran ring by a transannular cyclization of δ-hydroxy alkene using mercuric trifluoroacetate. Two of the six stereocenters C-5 and C-11 were realized from l-malic acid, while the remaining stereocenters C-3 (Sharpless asymmetric epoxidation), C-7 (transannular cyclization), C-9 (regioselective epoxide opening) and C-13 (chelation controlled reduction) were derived by asymmetric synthesis. The macrolactone ring was synthesized by macrocyclization using a RCM protocol.